Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurotrope Bioscience has entered into a license agreement with Icahn School of Medicine at Mount Sinai to use its information and data package for the development of Bryostatin-1 to treat Niemann-Pick Type C Disease (NPC).
Subscribe to our email newsletter
NPC is a rare disease seen mostly of children who are afflicted with Alzheimer-like symptoms.
According to the company, the licence also covers other diseases and disorders relying on activation of PKCepsilon, an enzyme that is important to the health of certain cells.
As part of the deal, Mount Sinai will receive an up-front licensing fee and an annual maintenance fee from Neurotrope Bioscience, while it will also receive payments based on predetermined product development milestones.
Additionally, Neurotrope will pay Mount Sinai a portion of consideration received from sub-licensees and a royalty on commercial net sales of products.
The company is carrying out the development program in partnership with Mount Sinai Genetics and Genomic Sciences Dr Yiannis Ioannou.
In addition, Neurotrope has applied for a provisional patent in the US to protect their ability to use and commercialize bryostatin technology for this disease indication.
Neurotrope co-chairmen and co-CEOs Paul Freiman and Charles Ramat jointly said the company is happy that Mount Sinai and Dr Ioannou wish to participate in this important step in furthering its strategic plan to be involved in orphan diseases which exhibit progressive loss of neurological functions.
"The submission of our joint provisional patent application further supports our belief in the therapeutic potential of bryostatin as an effective therapy in Alzheimer’s and other neurodegenerative diseases, the joint statement noted.